Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.

ABSTRACT:

Background

Relatively little is known about the use patterns of potential pharmacologic treatments of COVID-19 in the United States.

Objective

To use the National COVID Cohort Collaborative (N3C), a large, multicenter, longitudinal cohort, to characterize the use of hydroxychloroquine, remdesivir, and dexamethasone, overall as well as across individuals, health systems, and time.

Design

Retrospective cohort study.

Setting

43 health systems in the United States.

Participants

137 870 adults hospitalized with COVID-19 between 1 February 2020 and 28 February 2021.

Measurements

Inpatient use of hydroxychloroquine, remdesivir, or dexamethasone.

Results

Among 137 870 persons hospitalized with confirmed or suspected COVID-19, 8754 (6.3%) received h

SUBMITTER: Mehta HB 

PROVIDER: S-EPMC8372837 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature